Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 05, 2025 08:00 ET | Source: Chemomab Therapeutics

Chemomab Announces Presentation of Positive Nebokitug Phase 2 Clinical Data in Primary Sclerosing Cholangitis in Distinguished Plenary Session at DDW 2025

Positive data from the Phase 2 SPRING trial of nebokitug in PSC was presented in an oral Distinguished Abstract Plenary session at DDW 2025
March 06, 2025 08:00 ET | Source: Chemomab Therapeutics

New Data Presented at CORA 2025 Conference Highlights Clinical Potential of Chemomab’s Nebokitug in Systemic Sclerosis

Many preclinical and patient sample studies and positive Phase 2 PSC data suggest nebokitug is potentially a promising new treatment for systemic sclerosis
July 15, 2024 08:00 ET | Source: Assembly Biosciences, Inc.

Assembly Biosciences Presents New Preclinical Data Highlighting Investigational Helicase-Primase Inhibitors at International Herpesvirus Workshop

– Data from both ABI-5366 and ABI-1179, novel long-acting helicase-primase inhibitor candidates for recurrent genital herpes, to be presented – – Poster presentation highlights key preclinical data...
May 22, 2024 08:00 ET | Source: Assembly Biosciences, Inc.

Assembly Biosciences to Present Data at Upcoming International Herpesvirus Workshop and EASL Congress™ 2024

-- Preclinical data from both ABI-5366 and ABI-1179, Assembly Bio’s long-acting helicase-primase inhibitor candidates targeting recurrent genital herpes, featured in poster and oral presentations at...
November 10, 2023 08:00 ET | Source: Assembly Biosciences, Inc.

Assembly Biosciences Presents New Data Highlighting Viral Hepatitis Portfolio at AASLD The Liver Meeting®

--Poster highlights potential of oral small molecule IFNAR agonist program to engage the IFNα pathway through a liver-focused approach to improve tolerability-- SOUTH SAN FRANCISCO, Calif., Nov. 10,...
October 11, 2023 08:00 ET | Source: Assembly Biosciences, Inc.

Assembly Biosciences to Present New Data at AASLD The Liver Meeting®

-- One poster and one oral presentation selected, with the poster highlighting new preclinical data from the Company’s interferon-α receptor agonist program -- SOUTH SAN FRANCISCO, Oct. 11, 2023 ...
September 19, 2023 16:05 ET | Source: Assembly Biosciences, Inc.

Assembly Biosciences to Highlight Pipeline Progress in HBV and HDV at the 2023 International HBV Meeting

-- Two oral presentations and one poster will feature new data from the Company’s hepatitis B/hepatitis D entry inhibitor, capsid assembly modulator ABI-4334, and interferon-alpha receptor agonist...
July 17, 2023 08:00 ET | Source: Assembly Biosciences, Inc.

Assembly Biosciences Presents New Data Highlighting Herpes Simplex Virus Development Candidate ABI-5366 at the 47th Annual International Herpesvirus Workshop

-- First presentation of preclinical data describing the activity, pharmacokinetics and safety profile of ABI-5366, supporting planned clinical entry in 1H 2024 -- SOUTH SAN FRANCISCO, Calif.,...
June 21, 2023 08:00 ET | Source: Assembly Biosciences, Inc.

Assembly Biosciences Presents New Data Highlighting Entry Inhibitor and Core Inhibitor Programs at EASL’s International Liver Congress™ 2023

SOUTH SAN FRANCISCO, Calif., June 21, 2023 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative antiviral therapeutics targeting serious viral...
September 21, 2020 07:00 ET | Source: Cyclacel

Cyclacel Announces Fadraciclib Abstract Selected for Oral Presentation in the Late Breaking and Best Proffered Paper Session at the 32nd EORTC-NCI-AACR Symposium 2020

BERKELEY HEIGHTS, N.J., Sept. 21, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC) (Nasdaq: CYCCP) (Cyclacel or the Company), a biopharmaceutical company developing innovative...